More than 1 million people in the U.S. are currently living with Parkinson's disease. CBS News New York sports producer Joe McLaughlin shared his Parkinson's journey with.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Hundreds of participants gathered in Lincoln Park for the 15th annual Moving Day Chicago Walk to raise awareness and funds ...
Deep brain stimulation of the subthalamic nucleus has long been one of the most dramatic interventions in neurology: ...
Gain Therapeutics, Inc. announced the presentation of a poster at the International Congress of Parkinson?s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. The poster ...
This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...
In this Clinical Rounds, we present a case of neuroborreliosis in a man aged 59 years who initially complained of headache, ...
The results of a retrospective study of patients with Gaucher disease (GD) type 1 may support earlier screening for Parkinson ...
The allowance strengthens the intellectual property portfolio for trofinetide and extends protections in the U.S. from July 2036 to March 2041. Acadia Pharmaceuticals Inc. (Nas ...
Ana Navarro said Al Cárdenas' diagnosis left her wondering whether their lives were over. MEGA; @ANANAVARROFL/ INSTAGRAM Ana ...
DRI Healthcare expects a Sept. 29 close on US$316M in Juvmo rights after FDA approval; total receipts are capped at US$437.5M ...
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today commented on the U.S. Food and Drug Administration's ("FDA") recently announced approval of Juvmo (tavapadon) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results